top of page

Sofinnova Investments' Jakob Dupont on the private markets in biotech

Jakob Dupont says he is focused on clinical stage companies or ones that are months within IND. He thinks the IPO market will be available for advanced companies in 2024.


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page